

http://tucson.com/business/fda-fast-tracks-cancer-drug-developed-by-tucson-startup/article_8d821d64-9c9d-11e7-a738-336e7917e573.html

FDA 'fast tracks' cancer drug developed by Tucson startup

Arizona Daily Star Sep 18, 2017 Updated 20 hrs ago



Thinkstockphotos

Federal regulators have granted “Fast-Track” status to a drug developed by Tucson-based startup Cancer Prevention Pharmaceuticals Inc. for treatment of a rare genetic disease that usually leads to colon cancer.

The decision by the U.S. Food and Drug Administration potentially allows a streamlined path to market for the company's lead drug candidate, CPP-1X, in combination with another drug for treatment of familial adenomatous polyposis, said Jeff Jacob, Cancer Prevention's chairman and CEO.

The FDA had previously granted the drug combo "orphan drug" status, which gives drugmakers financial incentive to help drive development of treatments for rare diseases.

The FDA's Fast Track designation aims to expedite the review of drugs that treat serious conditions and fill unmet medical needs, making them eligible for accelerated approval and priority review if certain criteria are met.



Lung Cancer Symptoms

What are the symptoms of lung cancer?